The Neuro-Ophthalmology Division of the Wilmer Eye Institute is working on the following research projects.
- Assessing the benefit of stem cells in the reversal of visual loss due to optic nerve disease
- Using various drugs to reduce or prevent visual loss from optic nerve stroke
Ongoing Clinical Trials
Patients interested in enrolling in any of these trials should contact Priscilla Murdock at 410-502-3213 for more information and to determine eligibility.
Proteomics and Genomics of Giant Cell Arteritis: We are conducting proteomic and genomic screening of temporal artery specimens and blood from patients undergoing temporal artery biopsy for suspected GCA to identify potential pathogenic traits or organisms. To date we have identified a possible non-pathogenic bacterium that may be responsible for initiating the inflammatory cascade.
Closing date: June 2014
Celecoxib in Thyroid Eye Disease: To determine the efficacy of celecoxib in preventing disease progression in patients with active, mild-to-moderate thyroid eye disease of less than 6 months duration.
Closing date: August 2015
OCTiMS (OCT in MS): To establish a longitudinal database of RNFL and macular volume data in patients with clinically definite MS and to correlate changes with MRI change and clinical disease activity.
Closing date: July 2017